ALC ALCON INC IFRS
Ophthalmic Goods · NYSE · SEC CIK 1167379 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2020Q2*2020-06-30 | 2019Q2*2019-06-30 | 2018Q2*2018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.60B | $2.50B | $2.42B | $2.22B | $2.11B | $1.21B | $1.90B | $1.82B |
| Cost of revenue | $1.20B | $1.11B | $1.04B | $999.00M | $875.00M | $854.00M | $922.00M | $942.00M |
| Gross profit | $1.39B | $1.37B | $1.36B | $1.20B | $1.22B | $345.00M | $947.00M | $878.00M |
| R&D expense | $245.00M | $220.00M | $217.00M | $181.00M | $178.00M | $163.00M | $167.00M | $152.00M |
| SG&A expense | $870.00M | $837.00M | $832.00M | $803.00M | $785.00M | $595.00M | $760.00M | $722.00M |
| Operating income | $247.00M | $318.00M | $270.00M | $200.00M | $229.00M | -$466.00M | -$53.00M | $38.00M |
| Interest expense | $51.00M | $50.00M | $48.00M | $31.00M | $30.00M | $30.00M | $35.00M | $6.00M |
| Pretax income | $199.00M | $280.00M | $213.00M | $147.00M | $191.00M | -$502.00M | -$96.00M | $24.00M |
| Income tax | $23.00M | $57.00M | $44.00M | -$1.00M | $40.00M | -$80.00M | $294.00M | $9.00M |
| Net income | $176.00M | $223.00M | $169.00M | $148.00M | $151.00M | -$422.00M | -$390.00M | $15.00M |
| EPS (basic) | 0.36 | 0.45 | 0.34 | 0.30 | 0.31 | -0.86 | -0.80 | 0.03 |
| EPS (diluted) | 0.35 | 0.45 | 0.34 | 0.30 | 0.31 | -0.86 | -0.80 | 0.03 |
| Weighted avg. shares (diluted) | 497.90M | 497.00M | 495.70M | 494.30M | 493.20M | 489.00M | 488.20M | 488.20M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.41B | $1.37B | $661.00M | $1.03B | $1.37B | $1.32B | $721.00M | $151.00M |
| Short-term investments | $0 | — | — | — | — | — | — | — |
| Receivables | $1.99B | $1.83B | $1.79B | $1.60B | $1.46B | $1.17B | $1.41B | — |
| Inventory | $2.39B | $2.33B | $2.27B | $1.99B | $1.80B | $1.66B | $1.49B | — |
| Current assets | $6.31B | $5.99B | $5.20B | $5.02B | $5.02B | $4.63B | $4.14B | — |
| PP&E, netmay include right-of-use assets (IFRS) | $4.61B | $4.33B | $4.09B | $3.74B | $3.44B | $3.14B | $2.89B | — |
| Goodwill | $9.18B | $8.93B | $8.97B | $8.90B | $8.90B | $8.90B | $8.90B | — |
| Intangibles | $9.20B | $8.76B | $9.37B | $8.81B | $9.19B | $9.69B | $10.72B | — |
| Total assets | $31.39B | $29.72B | $29.21B | $27.73B | $27.75B | $27.48B | $27.77B | — |
| Current liabilities | $2.42B | $2.34B | $2.41B | $2.32B | $2.20B | $2.08B | $3.82B | — |
| Short-term debt | $81.00M | $137.00M | $100.00M | $87.00M | $136.00M | $235.00M | $1.77B | — |
| Long-term debt | $4.66B | $4.55B | $4.58B | $3.88B | $3.99B | $3.91B | $1.75B | — |
| Total debt | $4.75B | $4.69B | $4.68B | $3.97B | $4.12B | $4.14B | $3.52B | — |
| Total liabilities | $9.26B | $8.78B | $9.27B | $8.19B | $8.69B | $8.71B | $8.32B | — |
| Shareholders' equity | $22.11B | $20.94B | $19.94B | $19.54B | $19.06B | $18.77B | $19.45B | $22.73B |
| Net debt | $3.34B | $3.31B | $4.02B | $2.94B | $2.76B | $2.82B | $2.80B | — |
| Shares outstanding | 494.40M | 494.50M | 493.10M | 491.60M | 490.00M | 489.10M | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.